| Literature DB >> 35670907 |
Anish Nag1, Preeti Verma2, Subhabrata Paul3, Rita Kundu4.
Abstract
Occurrence of cervical cancer, caused due to persistent human papilloma virus (HPV) infection, is common in women of developing countries. As the conventional treatments are expensive and associated with severe side effects, there is a need to find safer alternatives, which is affordable and less toxic to the healthy human cells. Present study aimed to evaluate the anti-HPV and apoptotic potential of four compounds from the greater cardamom (Amomum subulatum Roxb. var. Golsey), namely rhein, phytosphingosine, n-hexadecenoic acid and coronarin E. Their anti-HPV and apoptotic potential were studied against viral E6, E7 and few anti-apoptotic proteins of host cell (BCL2, XIAP, LIVIN) by in silico docking technique. Phytochemicals from the plant extract were analysed and identified by LC/MS and GC/MS. Involvement of the target proteins in various biological pathways was determined through KEGG. Structural optimization of the three-dimensional structures of the ligands (four phytochemicals and control drug) was done by Avogadro1.1. Receptor protein models were built using ProMod3 and other advanced tools. Pharmacophore modelling of the selected phytochemicals was performed in ZINCPharmer. Swiss ADME studies were undertaken to determine drug likeness. The ligands and proteins were digitally docked in DockThor docking program. Protein flexibility-molecular dynamic simulation helped to study protein-ligand stability in real time. Finally, the correlation of evaluated molecules was studied by the use of principal component analysis (PCA) based on the docking scores. All the ligands were found to possess apoptotic and anti-cancer activities and did not violate Lipinsky criteria. n-Hexadecanoic acid and its analogues showed maximum efficacy against the target proteins. All the protein-ligand interactions were found to be stable. The uncommon phytochemicals identified from rhizomes of greater cardamom have anti-cancer, apoptotic and HPV inhibitory potentials as analysed by docking and other in silico studies, which can be utilized in drug development after proper experimental validation.Entities:
Keywords: Apoptosis; Docking; HPV; In silico analysis; Large cardamom; Phytochemicals
Mesh:
Substances:
Year: 2022 PMID: 35670907 PMCID: PMC9171093 DOI: 10.1007/s12010-022-04006-3
Source DB: PubMed Journal: Appl Biochem Biotechnol ISSN: 0273-2289 Impact factor: 3.094
Grid parameters
| S/N | Proteins | Centre grid parameters |
|---|---|---|
| 1 | XIAP | − 41.9855 × 139.931 × 15.3355 |
| 2 | LIVIN | 112.459 × 137.2445 × 174.7715 |
| 3 | BCL2 | 33.446 × − 14.0395 × − 14.7705 |
| 4 | E6 | 2 × 60 × 29 |
| 5 | E7 | 16.954 × 22.4675 × 40.3375 |
Fig. 1KEGG pathways derived integrated HPV-induced canonical cervical cancer pathways and corresponding therapeutic consequences resulting from drug application leading to apoptotic cellular death or cell cycle arrest
Fig. 2Functional descriptors of identified phytochemicals from Amomum subulatum rhizome used as pharmacophores as generated by PubChem and ZINCPharmer
ZINC small molecules screened based on phytochemical pharmacophores
| Phytochemical | Small molecules based on phytochemical pharmacophores | |||
|---|---|---|---|---|
| Analogues (ZINC id) | Chemical name of the analogues | RMSD (Å) | Mass | |
| Coronarin E (CID 9,971,144) | ZINC43742965 | [(2R,4aR,5R,8aS)-1,1,4a-trimethyl-6-methylidene-5-[(2-oxochromen-7-yl)oxymethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-2-yl] acetate (polyanthin) | 0.235 | 425 |
| ZINC12231395 | 8-(3,5-dimethylpyrazol-1-yl)-3,7-dimethyl-1-(2-phenylethyl)purine-2,6-dione | 0.630 | 378 | |
| ZINC09794889 | (2S)-N-benzhydryl-2-[[4-(2-fluorophenyl)-1,2,4-triazol-3-yl]sulfanyl]propanamide | 0.683 | 433 | |
| n-Hexadecanoic acid (PCID 985) | ZINC13368240 | 2-(4-fluorophenoxy)-N-[4-[[2-(2-methylpropyl)-5-oxo-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl]methoxy]phenyl]acetamide | 0.675 | 483 |
| ZINC13368607 | 2-(3,4-dimethylphenoxy)-N-[4-[(5-oxo-2-propyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl)methoxy]phenyl]acetamide | 0.715 | 479 | |
| ZINC08603481 | (E)-2-cyano-N-(4-fluorophenyl)-3-[4-[(2-methyl-5-oxo-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl)methoxy]phenyl]prop-2-enamide) | 0.544 | 461 | |
| Phytosphingosine (CID 122,121) | ZINC08781724 | (5S)-N'-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-N'-methyl-3-[(3S)-3-methyl-5-oxo-1-phenyl-1,2,4-triazolidin-3-yl]-4,5-dihydro-1,2-oxazole-5-carbohydrazide) | 0.511 | 498 |
| ZINC08964497 | Ethyl (3S)-3-[(4aR,6aS,6bS,7aR)-2-acetoxy-4a,6a-dimethyl-1,2,3,4,4a,4b,5,6,6a,7a,8,8a,8b,9-tetradecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-b]oxiren-6b-yl]-3-hydroxybutanoate | 0.606 | 461 | |
| ZINC59385771 | (4S)-4-(2,4-dihydroxyphenyl)-N'-{(E)-[4-(dimethylamino)phenyl]methylene}-6-methyl-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarbohydrazide | 0.536 | 409 | |
| Rhein (CID 10,168) | ZINC03875972 | 1,4-dihydroxy-9,10-dioxoanthracene-2-sulfonic acid (rufianic acid) | 0.435 | 319 |
| ZINC03977762 | 4,5,7-trihydroxy-9,10-dioxoanthracene-2-carboxylic acid (emodic acid) | 0.044 | 299 | |
| ZINC34053106 | 5-acetyloxy-4-hydroxy-9,10-dioxoanthracene-2-carboxylic acid | 0.044 | 325 | |
Fig. 32D structures of selected phytochemicals and associated ZINC analogues
Fig. 4Evaluation of drug-like properties of ligands, represented by Boiled-Egg graph; yellow yolk: blood–brain barrier permeate; white, gastro-intestinal absorption
Evaluation of drug likeliness by SwissADME
| Molecule | TPSA | iLOGP | XLOGP3 | ESOL log S | ESOL class | GI absorption | BBB permeate | Pgp substrate | Lipinski #violations |
|---|---|---|---|---|---|---|---|---|---|
| Kaempferol | 111.13 | 1.7 | 1.9 | − 3.31 | Soluble | High | No | No | 0 |
| Ciglitazone | 80.7 | 2.82 | 4.72 | − 4.74 | Moderately soluble | High | No | No | 0 |
| Coronarin E | 13.14 | 3.86 | 6.19 | − 5.55 | Moderately soluble | Low | No | No | 1 |
| ZINC43742965 | 65.74 | 3.86 | 5.52 | − 5.86 | Moderately soluble | High | No | No | 1 |
| ZINC12231395 | 79.64 | 3.72 | 2.63 | − 4.11 | Moderately soluble | High | No | No | 0 |
| ZINC09794889 | 85.11 | 3.27 | 4.97 | − 5.67 | Moderately soluble | High | No | Yes | 1 |
| n-Hexadecenoic acid | 37.3 | 3.85 | 7.17 | − 5.02 | Moderately soluble | High | Yes | No | 1 |
| ZINC13368240 | 123.06 | 3.63 | 3.94 | − 5.11 | Moderately soluble | High | No | No | 0 |
| ZINC13368607 | 123.06 | 3.94 | 4.13 | − 5.21 | Moderately soluble | High | No | No | 0 |
| ZINC08603481 | 137.62 | 3.41 | 3.54 | − 4.94 | Moderately soluble | Low | No | No | 0 |
| Phytosphingosine | 86.71 | 4.23 | 4.64 | − 3.68 | Soluble | High | No | Yes | 0 |
| ZINC08781724 | 111.19 | 2.73 | 3.07 | − 4.66 | Moderately soluble | High | No | Yes | 0 |
| ZINC08964497 | 85.36 | 4.37 | 3.53 | − 4.46 | Moderately soluble | High | No | No | 0 |
| ZINC59385771 | 126.29 | 2.06 | 1.48 | − 3.21 | Soluble | High | No | Yes | 0 |
| Rhein | 111.9 | 1.37 | 2.23 | − 3.36 | Soluble | High | No | No | 0 |
| ZINC03875972 | 140.18 | 0.19 | 2.01 | − 3.42 | Soluble | High | No | No | 0 |
| ZINC03977762 | 134.96 | 0.93 | 1.88 | − 3.22 | Soluble | High | No | No | 0 |
| ZINC34053106 | 120.8 | 1.79 | 2.34 | − 3.5 | Soluble | High | No | No | 0 |
GI, gastro-intestinal; BBB, blood–brain barrier
Binding affinities (kcal mol.−1) of phytochemicals and subsequent pharmacophore modelled compounds with target proteins interactions as obtained by DockThor
| Compounds | Binding affinity (kcal mol−1) | |||||
|---|---|---|---|---|---|---|
| XIAP | LIVIN | BCL2 | E6 | E7 | ||
| Natural control: kaempferol (CID 5,280,863) | − 8.252 | − 7.470 | − 7.664 | − 8.389 | − 7.595 | |
| Synthetic control: ciglitazone (CID 2750) | − 8.055 | − 7.477 | − 8.493 | − 7.246 | − 7.854 | |
| Coronarin E (CID 9,971,144) | − 7.948 | − 8.101 | ||||
| Coronarin E analogues | ZINC43742965 | |||||
| ZINC12231395 | − 7.525 | − 8.013 | ||||
| ZINC09794889 | − 8.216 | − 7.877 | − 7.679 | |||
| n − Hexadecanoic acid (CID 985) | − 7.353 | − 6.411 | − 6.429 | − 7.855 | − 6.616 | |
| n − Hexadecanoic acid analogues | ZINC13368240 | |||||
| ZINC13368607 | − 7.892 | |||||
| ZINC08603481 | − 7.749 | |||||
| Phytosphingosine (CID 122,121) | − 7.878 | − 7.047 | − 7.410 | − 7.176 | − 7.428 | |
| Phytosphingosine analogues | ZINC08781724 | − 7.436 | − 7.604 | − 8.055 | − 7.315 | |
| ZINC08964497 | − 7.318 | |||||
| ZINC59385771 | − 7.694 | − 7.458 | − 7.471 | − 7.074 | ||
| Rhein (CID 10,168) | − 6.434 | − 7.425 | − 6.682 | − 8.008 | − 7.679 | |
| Rhein analogues | ZINC03875972 | − 6.812 | − 7.320 | − 6.660 | − 7.445 | |
| ZINC03977762 | − 6.551 | − 7.226 | − 6.527 | − 8.045 | − 7.663 | |
| ZINC34053106 | − 7.183 | − 7.099 | − 6.925 | − 7.833 | − 6.761 | |
Bold, binding affinities higher than controls; Underline, best rank ligand for each of the proteins
Amino acid interaction between the best ranked ligands and proteins
| Compounds | Proteins | Amino acid interaction |
|---|---|---|
| Kaempferol | XIAP | GLU75A, GLU79A, LYS83A, TRP84A |
| Ciglitazone | ||
| ZINC13368607 | TRP71A, LYS72A, | |
| Kaempferol | LIVIN | ALA7A, LEU10A, HIS11A, ARG29A, ASP43A, |
| Ciglitazone | ||
| ZINC13368607 | MET1A, LYS8A, | |
| Kaempferol | BCL2 | GLU66A, ASP71A, GLY72A, HIS115A |
| Ciglitazone | ASP34A, ARG38A, TYR133A, SER136A | |
| ZINC08964497 | PHE35A, | |
| Kaempferol | E6 | LEU49C, CYS50C, VAL61C, SER73C |
| Ciglitazone | ||
| ZINC08603481 | ARG7C, ARG9C, VAL30C | |
| Kaempferol | E7 | ASP13B, GLU31B, LEU34B, MET35B |
| Ciglitazone | ARG17A, LEU18B, CYS19B, PRO43A, SER46A | |
| ZINC13368607 | HIS24B, ILE27B, ARG28B, |
Bold, common interacting amino acids of natural control kaempferol and ligands; Underline, common interacting amino acids of synthetic control ciglitazone and ligands
Fig. 5Interacting amino acid between the best ranked ligands and proteins
Fig. 6a Heat map binding affinity (kcal mol−1) of ligands and proteins. b Principal component analysis of docking results (kcal mol.−1)
Fig. 7Molecular alignment based on pharmacophores, as determined by PharmaGist. a Common aligned functional groups (dotted line) of PCA cluster 1 and (A1–A4): PCA cluster 1 compounds showing aligned functional groups (dotted line). b Common aligned functional groups (dotted line) of PCA cluster 3 and (B1-B4): PCA cluster 3 compounds showing aligned functional groups (dotted line)
Fig. 8The RMSF profiles of protein–ligand complexes as obtained by CABS-flex 2.0